Results 81 to 90 of about 148,910 (315)

Pharmacoeconomics of dapagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control

Качественная клиническая практика, 2018
Objectives. To evaluate the cost-effectiveness of dapagliflozin in combination with metformin in the treatment T2DM in comparison with glimepiride and sitagliptin also combined with metformin. Methods.
S. K. Zyryanov, M. F. Kalashnikova, D. Yu., E. V. Afanasyeva   +3 more
doaj  

Effects of metformin on human monocytic THP-1 cells - Implications for type 2 diabetes mellitus

, 2010
Metformin is an anti-hyperglycaemic agent widely prescribed for type 2 diabetes (T2D). Despite decades of clinical use, its exact pharmacological mechanism(s) is yet to be definitively determined.
Tsuei, An-Chi
core  

Beyond right or wrong: How partial credit scoring on multiple‐choice questions improves student performance and assessment perceptions

British Journal of Clinical Pharmacology, EarlyView.
Aims In this study, we examined the effects of assigning partial credit to selected answer choices on student performance and perceptions in a pharmacology course using Type A multiple‐choice questions (MCQs). Methods Partial credit scoring was incorporated into quizzes and exams in a 10‐week pharmacology course for postbaccalaureate premedical ...
Stephen D. Schneid, Chris Armour, Katharina Brandl   +2 more
wiley   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Metformin exhibited anticancer activity by lowering cellular cholesterol content in breast cancer cells.

PLoS ONE, 2019
Metformin, a widely prescribed anti-diabetic drug, shows anticancer activity in various cancer types. Few studies documented that there was a decreased level of LDL and total cholesterol in blood serum of metformin users. Based on these views, this study
Ankit Sharma, Shreetama Bandyopadhayaya, Kaushik Chowdhury, Tanu Sharma, Rekha Maheshwari, Amlan Das, Gopal Chakrabarti, Vipin Kumar, Chandi C Mandal   +8 more
doaj   +1 more source

Metformin in the management of diabetes during pregnancy and lactation

, 2018
This review explores the current place of metformin in the management of gestational diabetes (GDM) and type 2 diabetes during pregnancy and lactation.
Sanjay Kalra, Gagan Priya
core   +1 more source

Setting up mother–infant pair lactation studies with biobanking for research according to regulatory requirements

British Journal of Clinical Pharmacology, EarlyView.
Within the ConcePTION project we set out to design two mother–infant pair studies collecting breast milk and plasma from the mother and plasma from the infant (for metformin and prednisolone) in order to demonstrate the premises and conditions for investigating potential drug transfer in association with breastfeeding.
Mats Hansson, Ida Björkgren, Jenny Svedenkrans, Helena Backman, Jarl Hellman, Linda Englund‐Ögge, Mikaela Magnusson, Inger Lindström, Andrea Wutte, Erica Sundell, Pawel Baranczewski, Laura Shaughnessy   +11 more
wiley   +1 more source

Determination of metformin bio-distribution by LC-MS/MS in mice treated with a clinically relevant paradigm.

PLoS ONE, 2020
Metformin, an anti-diabetes drug, has been recently emerging as a potential "anti-aging" intervention based on its reported beneficial actions against aging in preclinical studies.
Kiran Chaudhari, Jianmei Wang, Yong Xu, Ali Winters, Linshu Wang, Xiaowei Dong, Eric Y Cheng, Ran Liu, Shao-Hua Yang   +8 more
doaj   +1 more source

Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies [PDF]

, 2009
Introduction Chronic low-grade inflammation is a significant factor in the development of obesity associated diabetes. This is supported by recent studies suggesting endotoxin, derived from gut flora, may be key to the development of inflammation by ...
Al-Attas, Omar S, Kumar Sudhesh, Shaun L Sabico, da Silva, Nancy F., Sabico, Shaun, McTernan Philip G, Sudhesh Kumar, Omar S Al-Attas, Al-Attas, Omar S., Harte, A. L. (Alison L.), Philip G McTernan, Al-Daghri, Nasser M., Al-Attas Omar S, Al-Rubeaan, Khalid, Alison L Harte, Khalid Al-Rubeaan, Nancy F da Silva, Sabico Shaun L, Kumar, Sudhesh, Al-Rubeaan Khalid, Nasser M Al-Daghri, da Silva Nancy F, Harte Alison L, Al-Daghri Nasser M, McTernan, P. G. (Philip G.)   +24 more
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source